What do i need to know about gout?

Journal of Family Practice

Volumn 59, Issue 6, 2010, Pages

  Becker, Michael A ^a   Ruoff, Gary E ^b,c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Westside Family Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; FEBUXOSTAT; MERCAPTOPURINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PROBENECID; THEOPHYLLINE; URATE;

ADULT; ANKLE PAIN; ARTHRALGIA; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CLINICAL TRIAL; COMORBIDITY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DIZZINESS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; FLUSHING; GOUT; HUMAN; HYPERURICEMIA; LOW DRUG DOSE; MALE; NAUSEA; OSTEOARTHRITIS; PHYSICIAN; RASH; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SIDE EFFECT; SYNOVIAL FLUID; TREATMENT PLANNING; URIC ACID BLOOD LEVEL; VOMITING; WALKING DIFFICULTY;

CLINICAL COMPETENCE; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MORBIDITY; PHYSICIANS, FAMILY; RISK FACTORS; URIC ACID;

EID: 77953742887     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med. 2008;75(suppl 5):S5-S8.
2. Dore RK. The gout diagnosis. Cleve Clin J Med. 2008;75(suppl 5):S17-S21.
3. Kirby BS, McTigue JC, Edwards NL. Pain management in gout. Curr Pain Headache Rep. 2008;12:418-422.
4. Zhang W, Doherty M, Pascual E, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1301-1311.
5. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med. 2008;359:1811-1821.
6. Krishnan E. Gout and coronary artery disease: epidemiologic clues. Curr Rheumatol Rep. 2008;10:249-255.
7. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2007;57:109-115. (Pubitemid 46256732)
8. Zhang W, Doherty M, Bardin T, et al; EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65:1312-1324.
9. Becker MA, Jolly M. Hyperuricemia and associated diseases. Rheum Dis Clin North Am. 2006;32:275-293, v-vi.
10. Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol. 2008;20:167-172. (Pubitemid 351339888)
11. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8(suppl 1):S2-S8. (Pubitemid 43919293)
12. Choi HK, Atkinson K, Karlson EW, et al. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350:1093-1103. (Pubitemid 38298989)
13. Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident goutin men: a prospective study. Lancet. 2004;363:1277-1281. (Pubitemid 38496489)
14. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ. 2008;336:309-312. (Pubitemid 351278368)
15. Choi JW, Ford ES, Gao X, et al. Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: the Third National Health and Nutrition Examination Survey. Arthritis Rheum. 2008;59:109-116.
16. Caspi D, Lubart E, Graff E, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43:103-108.
17. Dessein PH, Shipton EA, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis. 2000;59:539-543.
18. Rott KT, Agudelo CA. Gout. JAMA. 2003;289:2857-2860.
19. Pascual E, Doherty M. Aspiration of normal or asymptomatic pathological joints for diagnosis and research: indications, technique and success rate. Ann Rheum Dis. 2009;68:3-7.
20. Courtney P, Doherty M. Joint aspiration and injection and synovial fluid analysis. Best Pract Res Clin Rheumatol. 2009;23:161-192.
21. Nuki G. Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep. 2008;10:218-227.
22. So A, De Smedt T, Revaz S, et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther. 2007;9:R28.
23. Chen CJ, Shi Y, Hearn A, et al. MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest. 2006;116:2262-2271.
24. Janssens HJ, Lucassen PL, Van de Laar FA, et al. Systemic corticosteroids for acute gout. Cochrane Database Syst Rev. 2008;(2):CD005521.
25. Janssens HJ, Janssen M, Van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371:1854-1860.
26. Schlesinger N, Schumacher R, Catton M, et al. Colchicine for acute gout. Cochrane Database Syst Rev. 2006;(4):CD006190.
27. Terkeltaub RA, Furst DE, Bennett K, et al. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010;62:1060-1068.
28. Colcrys [prescribing information]. Philadelphia, PA: AR Scientific, Inc.; 2009.
29. Terkeltaub RA. Colchicine update: 2008. Semin Arthritis Rheum. 2009;38:411-419.
30. Singh H, Torralba KD. Therapeutic challenges in the management of gout in the elderly. Geriatrics. 2008;63:13-18, 20.
31. Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47:356-360.
32. Borstad GC, Bryant LR, Abel MP, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31:2429-2432.
33. Paulus HE, Schlosstein LH, Godfrey RG, et al. Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum. 1974;17:609-614.
34. Anon. Febuxostat (Uloric) for chronic treatment of gout. Med Lett Drugs Ther. 2009;51:37-38.
35. Allopurinol [prescribing information]. Corona, CA: Watson Laboratories, Inc.; 2006.
36. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353:2450-2461.
37. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57:545-549.
38. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc. 2006;81:925-934.
39. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56.
40. Dalbeth N, Kumar S, Stamp L, et al. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33:1646-1650.
41. Chao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep. 2009;11:135-140.
42. Stamp L, O'Donnell JL, Zhang W, et al. Increasing allopurinol dose above the recommended range is effective and safe in chronic gout, including those with renal impairment. Arthritis Rheum. 2009;60(suppl):S768-S773.
43. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27:337-343.
44. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59:1540-1548.
45. Becker MA, Schumacher HR, Espinoza LR, et al. The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther. 2010;12:R63.
46. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52:916-923.
47. Schumacher HR Jr, Chen LX. The practical management of gout. Cleve Clin J Med. 2008;75(suppl 5):S22-S25.